- Recruiting
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
Updated: Feb 7
MASTER-2
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow.
Sponsor
Collaborator
ClinicalTrials.gov Identifier: NCT05231629
Official Title: MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial
First Posted: February 9, 2022
Click here for details on ClinicalTrials.gov
Drug: Dara-VRd intensification, Dara-R maintenance
Drug: AHCT intensification, Dara-R maintenance
Drug: AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance
Drug: AHCT intensification, Dara-R consolidation, Dara-R maintenance
Drug: Dara-VRd induction
Locations
United States, Alabama
Related Post: